The 1st of September William Stafford, PhD joined Oxcia AB as Translational Director.
William has a background in oncology and redox-biology from the Karolinska Institutet. He developed his PhD work toward commercialization through Karolinska Institutet Innovations AB, leading to an exclusive licensing agreement with Oblique Therapeutics AB. At Oblique he became the head of small molecule discovery and preclinical development. Most recently, William has been leading search and evaluation activities at Olema Oncology through his company Fulgurite AB, expanding upon his global network of cancer therapy developing organizations and successfully delivering new assets through business development for an emerging pharmaceutical company.
